NEW YORK (GenomeWeb News) — Bar Harbor Biotechnology has closed a “multi-million dollar” round of Series A financing and plans to use the cash to market its first product, the company said Tuesday.
 
Bar Harbor Biotechnology, based in Trenton, Maine, is developing a suite of gene-expression products that includes bioanalysis software, qPCR arrays, and bioinformatics applications for gene-expression experiments.
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.